Press

Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs

Aug 19 • 3 min read

Quick Take: Cybin has filed two additional patents that claim a library of phenethlyamine and derivative drug development candidates. Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed two additional international patent applications that bring the potential to obtain patent coverage in 153 countries for each…

Core One Labs Acquires Frontier Mycology

Aug 18 • 3 min read

Quick Take: Core One Labs has acquired Frontier Mycology Corp. Frontier Mycology publishes news in the psychedelic space through its website MushroomNews.Org Core One Labs Inc. (CSE: COOL, OTC: CLABF), is a research and development company focused on bringing psychedelic medicines to market through the development and production of API grade psychedelic compounds, the advancement of…

Mydecine Innovations finishes 2Q with C$7M in cash after busy research period pinpoints four new lead drug candidates

Aug 17 • 2 min read

Quick Take: CEO Joshua Bartach told investors the company made “groundbreaking progress” and discoveries in its psilocybin compound research and drug development program The firm’s net loss for the period narrowed to C$3.8 million Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) reported its 2Q results showing the psychedelic firm ended the three-month period with C$7 million in cash…

Beckley Psytech completes oversubscribed $80m fundraise to develop portfolio of psychedelic medicine breakthroughs

Aug 17 • 5 min read

Quick Take: Privately held company Beckley Psytech has completed a Series B financing, raising $80m from VC investors. Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced it has successfully completed an oversubscribed Series B financing, raising $80m (£58m) from venture capital (VC)…

Ketamine One Subsidiary KGK Science Secures Multiple New Contracts

Aug 16 • 4 min read

Quick Take: KGK, a subsidiary of Ketamine One, is negotiating to secure over $2.3M of net new revenue. KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization, KGK…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435